The Half-Life Of Strategy Is Collapsing—How Boards Can Reframe Effective Oversight

The board problem is now hiding in plain sight: Strategy is not just being challenged more often. Its half-life is collapsing ...

Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); ...

Celldex Therapeutics, Inc.: Celldex Reports First Quarter Financial Results and Provides Corporate Update

Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for ...